FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs

CureVac (NASDAQ:CVAC) – Equities research analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for CureVac in a note issued to investors on Tuesday, May 20th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.68) for the year, up from their previous forecast of ($0.69). The consensus estimate for CureVac’s current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for CureVac’s Q4 2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.34) EPS.

CureVac (NASDAQ:CVAC) last posted its earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%.

A number of other research firms have also recently issued reports on CVAC. UBS Group cut their target price on CureVac from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. JMP Securities reiterated a “market outperform” rating and issued a $16.00 target price on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Performance

CVAC stock opened at $4.09 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The stock has a market capitalization of $917.54 million, a price-to-earnings ratio of 7.44 and a beta of 2.43. CureVac has a 1 year low of $2.37 and a 1 year high of $5.28. The stock’s fifty day moving average is $3.24 and its two-hundred day moving average is $3.29.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Greenleaf Trust acquired a new position in shares of CureVac during the first quarter valued at $31,000. Two Sigma Advisers LP acquired a new position in shares of CureVac during the fourth quarter valued at $48,000. Integrated Wealth Concepts LLC increased its holdings in shares of CureVac by 25.0% during the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after purchasing an additional 3,000 shares during the period. Jump Financial LLC acquired a new position in shares of CureVac during the fourth quarter valued at $55,000. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of CureVac during the fourth quarter valued at $66,000. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.